ホーム › 卵巣がん › メリーランド州 › Baltimore
Baltimore、MDにおける卵巣がんの臨床試験
Baltimoreとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する22件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
被験者募集中第2/3相
- University of Maryland/Greenebaum Cancer Center, Baltimore
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- University of Maryland/Greenebaum Cancer Center, Baltimore
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- Johns Hopkins University, Baltimore
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
被験者募集中第3相
- Research Site, Baltimore
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- University of Maryland, Baltimore /ID# 275308, Baltimore
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital Of Baltimore, Baltimore
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- United Theranostics, Glen Burnie · 9マイル先
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第2相
- Greater Baltimore Medical Center, Baltimore
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
被験者募集中第1/2相
- Research Site, Baltimore
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
被験者募集中第3相
- Greater Baltimore Medical Center, Towson · 8マイル先
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- The John Hopkins Hospital, Baltimore
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
被験者募集中第3相
- University of Maryland, Baltimore
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
被験者募集中第3相
- Greater Baltimore Medical Center, Towson · 8マイル先
EXoPERT EMERALD Clinical Study
被験者募集中観察研究健康なボランティア歓迎
- John Hopkins University, Baltimore
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
被験者募集中第1相
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
被験者募集中第2相
- SCRI - Maryland Oncology Hematology, P.A., Annapolis · 22マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · 8マイル先
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
被験者募集中第2相
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
被験者募集中観察研究
- Johns Hopkins University School of Medicine, Baltimore
- Anne Arundel Health System, Annapolis · 22マイル先
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
被験者募集中第1/2相
- Johns Hopkins, Baltimore
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
Baltimoreにおける他の研究
- 非小細胞肺癌60件の研究
- 乳がん47件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- がん（全種類）37件の研究
- 膵臓がん31件の研究
- 大腸癌31件の研究
- 転移性癌28件の研究
- 肥満症26件の研究
- 膀胱癌24件の研究
- 心不全24件の研究
- 脳卒中21件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。